VENLO, The Netherlands, October 7, 2011 - QIAGEN N.V.
VENLO, the Netherlands, June 15, 2011 - QIAGEN in exclusive negotiations to purchase 47% initial stake in Ipsogen S.A.and then fully acquire a global leader in hematologic (blood) cancer molecular diagnostics Ipsogen has a competitive portfolio in blood cancer testing with assays covering 15 biomarkers-including BCR-ABL and JAK2 -for patient profiling and monitoring Many of Ipsogen's assays have significant potential as companion diagnostics to help select and guide treatment decisions in personalized healthcare Addition of Ipsogen would strengthen QIAGEN's leadership in molecular diagnostics, significantly expanding its profiling and personalized healthcare portfolios QIAGEN N.V.
VENLO, Netherlands and MELBOURNE, Australia, April 3, 2011 - -- QIAGEN to acquire Cellestis Limited (CST:AU) via a Scheme of Arrangement (the Scheme) for approximately A$341 million(1) (US$355 million), or A$3.55 per share -- Unanimous support from Cellestis board of directors(2); QIAGEN granted options to acquire up to 19.9% of Cellestis ordinary shares under certain circumstances, subject to regulatory approvals -- Acquisition provides QIAGEN with exclusive access to QuantiFERON(R) technology for high sensitivity, early disease detection not possible with other diagnostic approaches -- QuantiFERON(R) technology successfully commercialized with two marketed Cellestis tests for detection of latent tuberculosis (TB) and life-threatening CMV virus -- QIAGEN to expand QuantiFERON(R) portfolio, migrate technology to QIAsymphony and QIAensemble platforms and leverage synergies with current QIAGEN assay portfolio and pipeline -- Acquisition would accelerate QIAGEN's sales and adjusted EPS growth rates in 2012 QIAGEN N.V.
VENLO, The Netherlands, September 1, 2010 - QIAGEN N.V.
VENLO, The Netherlands, February 8 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.